385 related articles for article (PubMed ID: 35732328)
21. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
22. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
23. Does the interval from tumour surgery to radiotherapy influence survival in paediatric high grade glioma?
Azizi AA; Paur S; Kaider A; Dieckmann K; Peyrl A; Chocholous M; Czech T; Slavc I
Strahlenther Onkol; 2018 Jun; 194(6):552-559. PubMed ID: 29349602
[TBL] [Abstract][Full Text] [Related]
24. Pediatric Gliomas: Molecular Landscape and Emerging Targets.
Peeters SM; Muftuoglu Y; Na B; Daniels DJ; Wang AC
Neurosurg Clin N Am; 2021 Apr; 32(2):181-190. PubMed ID: 33781501
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
26. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.
Schwark K; Messinger D; Cummings JR; Bradin J; Kawakibi A; Babila CM; Lyons S; Ji S; Cartaxo RT; Kong S; Cantor E; Koschmann C; Yadav VN
Front Oncol; 2022; 12():922928. PubMed ID: 35978801
[TBL] [Abstract][Full Text] [Related]
27. CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma.
Wenger A; Karlsson I; Kling T; Carén H
Clin Epigenetics; 2023 May; 15(1):80. PubMed ID: 37161535
[TBL] [Abstract][Full Text] [Related]
28. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract][Full Text] [Related]
29. Investigational new drugs for brain cancer.
Staedtke V; Bai RY; Laterra J
Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
[TBL] [Abstract][Full Text] [Related]
30. Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma.
Johns DA; Williams RJ; Smith CM; Nadaminti PP; Samarasinghe RM
Clin Transl Med; 2024 Feb; 14(2):e1560. PubMed ID: 38299304
[TBL] [Abstract][Full Text] [Related]
31. A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities.
McNicholas M; De Cola A; Bashardanesh Z; Foss A; Lloyd CB; Hébert S; Faury D; Andrade AF; Jabado N; Kleinman CL; Pathania M
Cancer Discov; 2023 Jul; 13(7):1592-1615. PubMed ID: 37011011
[TBL] [Abstract][Full Text] [Related]
32. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
33. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
34. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
[TBL] [Abstract][Full Text] [Related]
35. Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
Pal S; Kozono D; Yang X; Fendler W; Fitts W; Ni J; Alberta JA; Zhao J; Liu KX; Bian J; Truffaux N; Weiss WA; Resnick AC; Bandopadhayay P; Ligon KL; DuBois SG; Mueller S; Chowdhury D; Haas-Kogan DA
Cancer Res; 2018 Jul; 78(14):4007-4021. PubMed ID: 29760046
[TBL] [Abstract][Full Text] [Related]
36. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
37. H3.3
Pathania M; De Jay N; Maestro N; Harutyunyan AS; Nitarska J; Pahlavan P; Henderson S; Mikael LG; Richard-Londt A; Zhang Y; Costa JR; Hébert S; Khazaei S; Ibrahim NS; Herrero J; Riccio A; Albrecht S; Ketteler R; Brandner S; Kleinman CL; Jabado N; Salomoni P
Cancer Cell; 2017 Nov; 32(5):684-700.e9. PubMed ID: 29107533
[TBL] [Abstract][Full Text] [Related]
38. [Pediatric Hemispheric Glioma].
Nakano Y; Ichimura K; Sakamoto H
No Shinkei Geka; 2022 Jan; 50(1):122-131. PubMed ID: 35169092
[TBL] [Abstract][Full Text] [Related]
39. Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
Metselaar DS; Meel MH; Benedict B; Waranecki P; Koster J; Kaspers GJL; Hulleman E
EBioMedicine; 2019 Dec; 50():81-92. PubMed ID: 31735550
[TBL] [Abstract][Full Text] [Related]
40. Current and future directions for Phase II trials in high-grade glioma.
Alexander BM; Lee EQ; Reardon DA; Wen PY
Expert Rev Neurother; 2013 Apr; 13(4):369-87. PubMed ID: 23545053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
